Estrus synchronization in dairy goats: use of fluorogestone acetate vaginal sponges or norgestomet ear implants.
The ultimate aim of any estrus synchronization method is to allow artificial insemination at a predetermined time after the end of treatment. This requires a very tight synchronization of estrus which is not observed in goats after administration of the usual fluorogestone acetate (FGA)/prostaglandin (PG) F2 alpha/equine chorionic gonadotrophin (eCG) treatment. The possibility to improve the synchronization of estrus and luteinizing hormone (LH) peak with different progestagens (FGA versus norgestomet) and routes of administration (vaginal sponge versus subcutaneous ear implant) was evaluated in two experiments where goats received one of three progestagen treatments: (1) a vaginal sponge impregnated with 45 mg of FGA, (2) a half-implant of norgestomet, or (3) a whole implant containing 3 mg of norgestomet. The progestagens were left in place for 11 days and intramuscular injections of 400 or 500 IU of eCG (according to milk yield) and 50 micrograms of an analogue of PGF2 alpha (cloprostenol) were given 48 h prior to progestagen removal. In Experiment 1, 117 cycling goats were checked for the time of onset of estrus, preovulatory LH peak and ovulation rate following estrus synchronization treatment. Goats treated with half-implants came into estrus earlier than those receiving vaginal sponges (27.8 +/- 5.0 h vs. 33.0 +/- 6.6 h, respectively; P < 0.05). No effect of progestagen priming was observed on the variability of the onset of estrus. However, the interval between the time of onset of estrus and LH peak was more variable (P < 0.05) in goats treated with half-implants. In Experiment 2, 170 non-cycling goats were monitored for the time of onset of estrus, percentage of females ovulating, fertility and prolificacy after estrus induction treatment and artificial insemination with frozen-thawed semen performed 24 h after the onset of estrus. No effect of progestagen treatment was observed either on the time or the variability of onset of estrus. The percentage of goats ovulating and overall fertility rate were higher (P < 0.05) in goats receiving vaginal sponges (98.2% and 75.0%, respectively) than those treated with half-implants (81.8% and 45.5%, respectively). However, no significant difference was observed, for the same parameters, in animals receiving implants (86.3% and 58.8%, respectively). In conclusion, estrus synchronization with a norgestomet implant or half-implant did not reduce the variability in the onset of estrus and LH peak. The fertility tended to be lower in goats treated with a whole implant and was significantly decreased in goats which received a half-implant.
Freitas
V J
VJ
I.N.R.A. Reproductive Physiology of Domestic Mammals, Nouzilly, France.
Baril
G
G
Saumande
J
J
D000818:Animals; D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000494:pharmacology; D003008:Cloprostenol / Q000494:pharmacology; D015237:Dinoprost / Q000031:analogs & derivatives; D004343:Drug Implants; D004973:Estrus Synchronization / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005298:Fertility / Q000502:physiology; D003425:Flurogestone Acetate / Q000008:administration & dosage / Q000494:pharmacology*; D006041:Goats / Q000097:blood / Q000502:physiology*; D006736:Horses; D007273:Injections, Intramuscular; D007986:Luteinizing Hormone / Q000097:blood; D010570:Pessaries / Q000662:veterinary; D011282:Pregnenediones / Q000008:administration & dosage / Q000494:pharmacology*; D045167:Progesterone Congeners / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
D006063:Chorionic Gonadotropin; D004343:Drug Implants; D011282:Pregnenediones; D045167:Progesterone Congeners; C100284:norgestomet; D003008:Cloprostenol; D007986:Luteinizing Hormone; D015237:Dinoprost; D003425:Flurogestone Acetate